StockDrifts LogoStockDrifts

Billions 044480

Company
빌리언스Billions
Insiders
2
Buys
0
Total Value
₩940M ($653K)
Avg Return
+6.51%
Last Filing
2026-05-11

Billions (044480) has 0 disclosed insider purchases and 2 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩940M ($653K) in reported transaction value. The earliest filing StockDrifts holds for Billions is dated 2024-02-13; the most recent is 2026-05-11. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +6.51%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-05-11BUY장외매수
디지털브리지 신기술 투자조합
Digital Bridge New Technology Investment Association
-5.4M---
2026-04-21BUY행사가액조정
휴마시스
Humasis
-284.7K₩445+0.0%₩127M ($88K)
2026-04-21SELLMarket Sell
휴마시스
Humasis
--1.9M₩445+0.0%₩829M ($576K)
2026-04-21BUY유상신주취득
휴마시스
Humasis
-7.8M₩445+0.0%₩3.5B ($2.4M)
2026-04-17BUY행사가액조정
휴마시스
Humasis
-121.0K₩445+0.0%₩54M ($37K)
2026-04-16SELL행사가액조정
휴마시스
Humasis
--5.8M₩445+0.0%₩2.6B ($1.8M)
2026-04-16SELL주식병합
휴마시스
Humasis
--21.9M₩445+0.0%₩9.7B ($6.8M)
2026-04-01SELL행사가액조정
휴마시스
Humasis
--1.9M₩326-36.5%₩614M ($427K)
2026-03-31SELL임원퇴임
심화석
Shim Seok Sim
CEO-786.1K₩312-42.6%₩245M ($170K)
2026-03-03BUY행사가액조정
휴마시스
Humasis
-470.3K₩221+45.3%₩104M ($72K)
2026-03-03BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-1.2M₩221+45.3%₩263M ($182K)
2026-02-02BUY행사가액조정
휴마시스
Humasis
-887.1K₩269+19.3%₩239M ($166K)
2026-02-02BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-2.2M₩269+19.3%₩603M ($419K)
2026-01-02BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-1.4M₩301+6.6%₩435M ($302K)
2026-01-02BUY행사가액조정
휴마시스
Humasis
-571.6K₩301+6.6%₩172M ($119K)
2025-12-01BUY행사가액조정
휴마시스
Humasis
-1.0M₩323-0.6%₩325M ($226K)
2025-12-01BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-2.5M₩323-0.6%₩822M ($571K)
2025-11-03BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-2.4M₩350-8.3%₩835M ($580K)
2025-11-03BUY행사가액조정
휴마시스
Humasis
-944.1K₩350-8.3%₩330M ($229K)
2025-10-01SELL행사가액조정
경남제약
Kyungnam Pharmaceutical
--9.5M₩397+19.1%₩3.8B ($2.6M)
2025-10-01SELL행사가액조정
휴마시스
Humasis
--3.8M₩397+19.1%₩1.5B ($1.0M)
2025-09-13BUY행사가액조정
휴마시스
Humasis
-3.4M₩505-36.4%₩1.7B ($1.2M)
2025-09-13SELL기타
휴마시스
Humasis
--13.6M₩505+36.4%₩6.9B ($4.8M)
2025-09-13BUY유상신주취득
휴마시스
Humasis
-13.6M₩505-36.4%₩6.9B ($4.8M)
2025-09-13BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-10.5M₩505-36.4%₩5.3B ($3.7M)
2025-09-10BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-99.7K₩408-21.3%₩41M ($28K)
2025-09-05SELL기타
심화석
Shim Seok Sim
CEO-473.3K₩432+25.7%₩204M ($142K)
2025-09-01SELL행사가액조정
휴마시스
Humasis
--1.9M₩468+31.4%₩905M ($628K)
2025-09-01SELL행사가액조정
경남제약
Kyungnam Pharmaceutical
--4.9M₩468+31.4%₩2.3B ($1.6M)
2025-08-28SELLMarket Sell
심화석
Shim Seok Sim
CEO-300.0K₩369+13.0%₩111M ($77K)
2025-08-19BUY기타
심화석
Shim Seok Sim
CEO773.3K₩415-22.6%₩321M ($223K)
2025-08-11BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-203.0K₩570-43.7%₩116M ($80K)
2025-08-08BUY기타
휴마시스
Humasis
-13.6M₩439-26.9%₩6.0B ($4.1M)
2025-08-01BUY행사가액조정
휴마시스
Humasis
-2.8M₩303+5.9%₩860M ($597K)
2025-04-01BUY행사가액조정
휴마시스
Humasis
-524.0K₩416-22.8%₩218M ($151K)
2025-04-01BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-1.3M₩416-22.8%₩551M ($382K)
2025-03-04SELL행사가액조정
경남제약
Kyungnam Pharmaceutical
--1.3M₩447+28.2%₩592M ($411K)
2025-03-04SELL행사가액조정
휴마시스
Humasis
--524.0K₩447+28.2%₩234M ($163K)
2025-01-02BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-1.4M₩463-30.7%₩657M ($456K)
2025-01-02BUY행사가액조정
휴마시스
Humasis
-561.3K₩463-30.7%₩260M ($180K)
2024-12-10BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-573.5K₩460-30.2%₩264M ($183K)
2024-12-02BUY행사가액조정
휴마시스
Humasis
-217.1K₩480-33.1%₩104M ($72K)
2024-12-02BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-548.6K₩480-33.1%₩263M ($183K)
2024-11-10BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-64.4K₩573-44.0%₩37M ($26K)
2024-11-01BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-1.0M₩547-41.3%₩560M ($389K)
2024-11-01BUY행사가액조정
휴마시스
Humasis
-405.5K₩547-41.3%₩222M ($154K)
2024-10-10BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-133.9K₩654-50.9%₩88M ($61K)
2024-10-02BUY행사가액조정
휴마시스
Humasis
-352.3K₩645-50.2%₩227M ($158K)
2024-10-02BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-889.9K₩645-50.2%₩574M ($399K)
2024-09-10BUY행사가액조정
경남제약
Kyungnam Pharmaceutical
-13.1K₩638-49.7%₩8M ($6K)

Showing the 50 most recent of 80 filings.

Frequently asked questions

Who has been buying Billions stock?
2 distinct insiders have filed 0 disclosed insider purchases in Billions (044480), most recently on 2026-05-11. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Billions have?
Billions has 0 buy-side and 2 sell-side disclosures on record, covering ₩940M ($653K) in total reported value, spanning 2024-02-13 to 2026-05-11.
Where does StockDrifts get Billions insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Billions. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.